Ocular drug delivery is an innovative approach for treating retinal diseases, offering direct administration methods like intravitreal injections. This article provides an overview of nonclinical safety evaluation techniques for ocular drug delivery, highlighting the use of Cynomolgus macaques in preclinical trials.
Introduction to Ocular Drug Delivery
Compared to conventional administration routes such as oral, intramuscular, subcutaneous, or intravenous, direct ocular drug delivery, like intravitreal injections, is a relatively new method for developing biological drugs targeting retinal diseases. This article discusses the nonclinical safety evaluation techniques and methods for ocular drug delivery.
Guiding Principles
Currently, there are no specific guidelines from CDE, ICH, FDA, or EMA regarding nonclinical safety evaluations for ocular drug delivery. The OECD's Guidance No. 263 on severe eye damage and irritation tests provides some methods and recommendations but does not cover strategies or specific requirements for ocular drug delivery.
Selection of Experimental Animals
The eye consists of the eyeball wall and contents, with layers including the cornea, sclera, iris, ciliary body, and retina. Among experimental animals, the eyes of monkeys, dogs, and pigs are similar to humans. Cynomolgus macaques, in particular, have eyes that closely resemble human eyes in texture and structure, making them ideal for risk assessment.
Non-rodents such as rabbits, dogs, and monkeys are typically chosen for ocular toxicity and pharmacokinetic studies. Rabbits are commonly used due to the sufficient size of their eyes for accurate injections. However, the anatomical and physiological similarities of monkey eyes to human eyes, including the presence of the macula, make Cynomolgus macaques the preferred choice for biologics.
Methods of Ocular Drug Administration
Ocular toxicology requires specialized equipment, techniques, and experienced researchers with a strong background in ocular physiology and toxicology. Common methods of ocular drug delivery include:
- Subconjunctival Injection: Administered beneath the conjunctiva.
- Intravitreal Injection: Administered into the vitreous chamber.
- Subretinal Injection: Administered beneath the retina.
- Suprachoroidal Injection: Administered above the choroid.
Formulation Design
Designing formulations for ocular biologics involves finding the most reliable formulation matrix and choosing appropriate buffers and excipients. Poor formulation choices can lead to loss of active ingredient activity and immunogenicity, primarily due to the unique environment within the eye. It is crucial to select acceptable excipients, pH values, and osmolarity to ensure stability and safety. In vitro/in vivo correlation (IVIVC) analysis can predict product performance and support the development of better formulations.
Evaluation Indicators
In addition to general toxicity indicators, ocular toxicology includes specific ophthalmic indicators such as:
- General Ophthalmic Examination: Using slit lamps and ophthalmoscopes.
- Intraocular Pressure (IOP): Measured at different time points post-administration.
- Optical Coherence Tomography (OCT): Checks for structural abnormalities within the eye.
- Electroretinography (ERG): Assesses retinal function post-administration.
- Fluorescein Angiography (FFA) and Fundus Photography: Examines the structure and vascular morphology of the retina at various time points.
- Ocular Pathology: Detailed examination of the eye tissues.
Conclusion
Nonclinical safety evaluations for ocular drug delivery are crucial in developing new therapies for retinal diseases. Using Cynomolgus macaques provides a reliable model due to their anatomical and physiological similarities to humans. Accurate formulation design and comprehensive evaluation indicators are essential for successful ocular drug delivery.
By adhering to these guidelines and utilizing advanced techniques, researchers can ensure the safety and efficacy of ocular therapeutics, paving the way for innovative treatments for retinal diseases.
Keywords: Ocular Drug Delivery, Cynomolgus macaques, nonclinical safety evaluation, ocular toxicity, preclinical trials, eye drug delivery methods, ocular pharmacokinetics.
